Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors

Blood

Volumn 116, Issue 15, 2010, Pages 2656-2664

  Alba, Raul ^a   Bradshaw, Angela C ^a   Coughlan, Lynda ^a   Denby, Laura ^a   McDonald, Robert A ^a   Waddington, Simon N ^b   Buckley, Suzanne M K ^b   Greig, Jenny A ^a   Parker, Alan L ^a   Miller, Ashley M ^c   Wang, Hongjie ^d   Lieber, Andre ^d   Van Rooijen, Nico ^e   McVey, John H ^f   Nicklin, Stuart A ^a   Baker, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10 BINDING ABLATED ADENOVIRUS 5 VECTOR; GLYCOPROTEIN P 15095; MACROPHAGE INFLAMMATORY PROTEIN; MEMBRANE COFACTOR PROTEIN; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; UNCLASSIFIED DRUG; AUTACOID; BETA GALACTOSIDASE; CAPSID PROTEIN; CHEMOKINE; CYTOKINE; HEXON CAPSID PROTEIN, ADENOVIRUS; PROTEIN BINDING; RECOMBINANT PROTEIN;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; GENE LOCATION; GENETIC TRANSDUCTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SPLEEN; TRANSGENE; ANIMAL; CLASSIFICATION; GENE VECTOR; GENETICS; HUMAN; HUMAN ADENOVIRUS; LUNG; METABOLISM; SEROTYPING; TIME; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; VIROLOGY;

ADENOVIRUSES, HUMAN; ANIMALS; BETA-GALACTOSIDASE; CAPSID PROTEINS; CHEMOKINES; CYTOKINES; FACTOR X; GENETIC VECTORS; HUMANS; INFLAMMATION MEDIATORS; LIVER; LUNG; MALE; MICE; MICE, TRANSGENIC; PROTEIN BINDING; RECOMBINANT PROTEINS; SEROTYPING; SPLEEN; TIME FACTORS; TISSUE DISTRIBUTION; TRANSDUCTION, GENETIC;

EID: 77957953561     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-12-260026     Document Type: Article

References (42)

1. Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010;28(4):950-957.
2. Abbink P, Lemckert AA, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81(9):4654-4663. (Pubitemid 46668663)
3. Sumida SM, Truitt DM, Lemckert AA, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol. 2005;174(11):7179-7185.
4. Jaffe HA, Danel C, Longenecker G, et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet. 1992;1(5):372-378.
5. Tao N, Gao GP, Parr M, et al. Sequestration of adenoviral vector by Kupffer cells leads to a non-linear dose response of transduction in liver. Mol Ther. 2001;3(1):28-35. (Pubitemid 32509802)
6. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275(5304):1320-1323. (Pubitemid 27114163)
7. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A. 1997;94(7):3352-3356. (Pubitemid 27157315)
8. Einfeld DA, Brough DE, Roelvink PW, Kovesdi I, Wickham TJ. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J Virol. 1999;73(11):9130-9136. (Pubitemid 29487066)
9. Roelvink PW, Lizonova A, Lee JG, et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol. 1998;72(10):7909-7915. (Pubitemid 28421782)
10. 5 promote adenovirus internalization but not virus attachment. Cell. 1993;73(2):309-319.
11. Nemerow GR, Wickham TJ, Cheresh DA. The role of a5 integrins in adenovirus infection. New York: Elsevier Science Publishers; 1993.
12. Mizuguchi H, Koizumi N, Hosono T, et al. Car- or aV integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Therapy. 2002;9:769-776. (Pubitemid 34679304)
13. Koizumi N, Kawabata K, Sakurai F, Watanabe Y, Hayakawa T, Mizuguchi H. Modified Adenoviral Vectors Ablated for Coxsackievirus-Adenovirus Receptor, alpha v Integrin, and Heparan Sulfate Binding Reduce In Vivo Tissue Transduction and Toxicity. Human Gene Therapy. 2006;17:264-279.
14. Cotter M, Zaiss A, Muruve D. Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. J Virol. 2005;79(23):14622-14631. (Pubitemid 41636261)
15. Stone D, Ni S, Yi Li Z, Shayakhmetov D, Lieber A. Intravascular delivery of adenovirus vectors rapidly targets platelets to the reticuloendothelial system Mol Ther. 2006;13(1):S143-S144.
16. Nicol CG, Graham D, Miller WH, et al. Effect of adenovirus serotype 5 fiber and penton modifications on in vivo tropism in rats. Mol Ther. 2004;10(2):344-354. (Pubitemid 39117879)
17. Carlisle RC, Di Y, Cerny AM, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009;113(9):1909-1918.
18. Seiradake E, Henaff D, Wodrich H, et al. The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog. 2009;5(1):e1000277.
19. Wolff G, Worgall S, van Rooijen N, Song WR, Harvey BG, Crystal RG. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol. 1997;71(1):624-629. (Pubitemid 26412334)
20. Di Paolo NC, Miao EA, Iwakura Y, et al. Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity. 2009;31(1):110-121.
21. Jiang H, Wang Z, Serra D, Frank MM, Amalfitano A. Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther. 2004;10(6):1140-1142. (Pubitemid 39625257)
22. Xu Z, Tian J, Smith JS, Byrnes AP. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol. 2008;82(23):11705-11713.
23. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol. 2005;79(12):7478-7491. (Pubitemid 40756784)
24. Parker AL, Waddington SN, Nicol CG, et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood. 2006;108(8):2554-2561.
25. Waddington SN, Parker AL, Havenga M, et al. Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5. J Virol. 2007;81(17):9568-9571. (Pubitemid 47311502)
26. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008;132(3):397-409. (Pubitemid 351200513)
27. Alba R, Bradshaw AC, Parker AL, et al. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood. 2009;114(5):965-971.
28. Wang H, Liu Y, Li Z, et al. In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46. J Virol. 2008;82(21):10567-10579. (Pubitemid 352691205)
29. Smith TA, Idamakanti N, Marshall-Neff J, et al. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther. 2003;14(17):1595-1604. (Pubitemid 37452870)
30. Von Seggern DJ, Kehler J, Endo RI, Nemerow GR. Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein. J Gen Virol. 1998;79(Pt 6):1461-1468. (Pubitemid 28258457)
31. Greig JA, Buckley SM, Waddington SN, et al. Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors. Mol Ther. 2009;17(10):1683-1691.
32. van Rooijen N, Kors N, Kraal G. Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination. J Leukoc Biol. 1989;45(2):97-104. (Pubitemid 19077295)
33. Koizumi N, Yamaguchi T, Kawabata K, et al. Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J Immunol. 2007;178(3):1767-1773. (Pubitemid 46154648)
34. Hamid O, Varterasian ML, Wadler S, et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21(8):1498-1504. (Pubitemid 46594102)
35. Small EJ, Carducci MA, Burke JM, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006;14(1):107-117.
36. Raper SE, Yudkoff M, Chirmule N, et al. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther. 2002;13(1):163-175. (Pubitemid 34075180)
37. Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid TR. Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther. 2007;14(2):139-150. (Pubitemid 46106958)
38. Zhang Y, Chirmule N, Gao GP, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther. 2001;3(5 Pt 1):697-707. (Pubitemid 32509867)
39. Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol. 2005;5(8):606-616.
40. Alemany R. Cancer selective adenoviruses. Mol Aspects Med. 2007;28(1):42-58.
41. Shashkova EV, May SM, Doronin K, Barry MA. Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol Ther. 2009;17(12):2121-2130.
42. Vigant F, Descamps D, Jullienne B, et al. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol Ther. 2008;16(8):1474-1480.